Evil Diaries: Costly Reading
Michael Lewis’s book on Sam Bankman-Fried and his FTX concern is the book of the week on Radio 4 each day at 9.45 a.m.. It is most entertaining – unless of course one has lost money thereby. SBF’s trials continue.
As readers know I am addicted to asset situations, particularly tangible assets. One that popped up last week was Arix Bioscience (ARIX), now 120p to buy. There is an astonishing 90p a share in cash with the rest made up of listed and unlisted investments worth, seemingly, 90p+ a share. Further, the directors have declared that they will do something about this absurd state of affairs. I would take them at their word and squirrel a few away.
Poppy Gustafsson, CEO of DarkTrace (DARK) declines to go to America in the defence of her erstwhile boss, Mike Lynch. One can understand why. In the meantime, keep selling. Now 390p.
My tutorial sessions are proving attractive and I invite more to attend. My telephone number remains 020 7835 0868 and my email address is cawkwell@btinternet.com. My bait in the form of chocolate eclairs seems to be ignored by visitors. So I have to eat them. This is fattening.
Interested in your take on the half year results at REA.
The preference dividend maybe suspended again, the update will be late November.
Pref at 62p and ordinaries at 62p.
A 14.5% yield on the prefs if the payment is made and still a further 7p outstanding.
REA should be cutting costs to be profitable at palm oil $800 but seem to be adding to their cost base.